OA11398A - Anti-first-pass effect compounds. - Google Patents

Anti-first-pass effect compounds. Download PDF

Info

Publication number: OA11398A
Authority: OA; OAPI
Prior art keywords: citrus; alkyl; pass; compounds; water
Prior art date: 1997-08-26

Application number

OA1200000051A

Other languages

English (en)

Inventor

James W Harris

Original Assignee

Bioavailability Systems L L C

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-26

Filing date

2000-02-24

Publication date

2004-04-14

1997-12-23 Priority claimed from US08/997,259 external-priority patent/US6063809A/en

1997-12-30 Priority claimed from US09/001,218 external-priority patent/US6124477A/en

2000-02-24 Application filed by Bioavailability Systems L L C filed Critical Bioavailability Systems L L C

2004-04-14 Publication of OA11398A publication Critical patent/OA11398A/en

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 83
238000010579 first pass effect Methods 0.000 title abstract description 47
239000000203 mixture Substances 0.000 claims abstract description 85
235000020971 citrus fruits Nutrition 0.000 claims abstract description 71
241000207199 Citrus Species 0.000 claims abstract description 67
239000000126 substance Substances 0.000 claims abstract description 63
238000000034 method Methods 0.000 claims abstract description 42
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 57
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 36
238000000605 extraction Methods 0.000 claims description 17
235000019499 Citrus oil Nutrition 0.000 claims description 13
239000010500 citrus oil Substances 0.000 claims description 13
239000003921 oil Substances 0.000 claims description 13
235000019198 oils Nutrition 0.000 claims description 13
230000000694 effects Effects 0.000 claims description 11
229910052760 oxygen Inorganic materials 0.000 claims description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
239000001301 oxygen Substances 0.000 claims description 6
229920006395 saturated elastomer Polymers 0.000 claims description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
238000012545 processing Methods 0.000 claims description 4
125000001072 heteroaryl group Chemical group 0.000 claims description 3
125000004430 oxygen atom Chemical group O* 0.000 claims description 3
229910052717 sulfur Inorganic materials 0.000 claims description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
125000004429 atom Chemical group 0.000 claims description 2
229910052757 nitrogen Inorganic materials 0.000 claims description 2
125000006413 ring segment Chemical group 0.000 claims description 2
239000011593 sulfur Substances 0.000 claims description 2
125000004122 cyclic group Chemical group 0.000 claims 1
230000002401 inhibitory effect Effects 0.000 abstract description 19
238000009472 formulation Methods 0.000 abstract description 5
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 90
125000000217 alkyl group Chemical group 0.000 description 65
239000003814 drug Substances 0.000 description 54
229940079593 drug Drugs 0.000 description 48
239000000463 material Substances 0.000 description 29
239000003112 inhibitor Substances 0.000 description 23
239000000243 solution Substances 0.000 description 23
239000000047 product Substances 0.000 description 17
238000006243 chemical reaction Methods 0.000 description 15
235000013305 food Nutrition 0.000 description 15
238000004128 high performance liquid chromatography Methods 0.000 description 15
-1 naringin Chemical class 0.000 description 15
238000010828 elution Methods 0.000 description 13
235000011389 fruit/vegetable juice Nutrition 0.000 description 13
231100000760 phototoxic Toxicity 0.000 description 13
239000002585 base Substances 0.000 description 12
229910052799 carbon Inorganic materials 0.000 description 12
ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 12
238000002156 mixing Methods 0.000 description 11
235000011118 potassium hydroxide Nutrition 0.000 description 10
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 9
108010036949 Cyclosporine Proteins 0.000 description 9
239000007788 liquid Substances 0.000 description 9
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
229960000351 terfenadine Drugs 0.000 description 8
229930105110 Cyclosporin A Natural products 0.000 description 7
241000282412 Homo Species 0.000 description 7
229960001265 ciclosporin Drugs 0.000 description 7
239000000284 extract Substances 0.000 description 7
235000015201 grapefruit juice Nutrition 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
230000008569 process Effects 0.000 description 7
229960001852 saquinavir Drugs 0.000 description 7
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 7
BGEBZHIAGXMEMV-UHFFFAOYSA-N 5-methoxypsoralen Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC BGEBZHIAGXMEMV-UHFFFAOYSA-N 0.000 description 6
DBMJZOMNXBSRED-UHFFFAOYSA-N Bergamottin Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(C)CCC=C(C)C DBMJZOMNXBSRED-UHFFFAOYSA-N 0.000 description 6
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 6
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
239000010651 grapefruit oil Substances 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 5
240000000560 Citrus x paradisi Species 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
235000013399 edible fruits Nutrition 0.000 description 5
238000011160 research Methods 0.000 description 5
125000001424 substituent group Chemical group 0.000 description 5
NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
239000013543 active substance Substances 0.000 description 4
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 4
DBMJZOMNXBSRED-OQLLNIDSSA-N bergomottin Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC/C=C(C)/CCC=C(C)C DBMJZOMNXBSRED-OQLLNIDSSA-N 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
235000001671 coumarin Nutrition 0.000 description 4
150000004775 coumarins Chemical class 0.000 description 4
229930182912 cyclosporin Natural products 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 4
238000001914 filtration Methods 0.000 description 4
238000005194 fractionation Methods 0.000 description 4
OLOOJGVNMBJLLR-UHFFFAOYSA-N imperatorin Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OCC=C(C)C OLOOJGVNMBJLLR-UHFFFAOYSA-N 0.000 description 4
XKVWLLRDBHAWBL-UHFFFAOYSA-N imperatorin Natural products CC(=CCOc1c2OCCc2cc3C=CC(=O)Oc13)C XKVWLLRDBHAWBL-UHFFFAOYSA-N 0.000 description 4
239000002198 insoluble material Substances 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 4
229940002612 prodrug Drugs 0.000 description 4
239000000651 prodrug Substances 0.000 description 4
239000004215 Carbon black (E152) Substances 0.000 description 3
235000008733 Citrus aurantifolia Nutrition 0.000 description 3
RNKZFOIQKCQOAQ-UHFFFAOYSA-N Isopimpinellin Natural products COC1CC(=O)Oc2c(OC)c3occc3cc12 RNKZFOIQKCQOAQ-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 3
101150053185 P450 gene Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
240000006909 Tilia x europaea Species 0.000 description 3
235000011941 Tilia x europaea Nutrition 0.000 description 3
PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
239000003429 antifungal agent Substances 0.000 description 3
239000004599 antimicrobial Substances 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
229960002045 bergapten Drugs 0.000 description 3
KGZDKFWCIPZMRK-UHFFFAOYSA-N bergapten Natural products COC1C2=C(Cc3ccoc13)C=CC(=O)O2 KGZDKFWCIPZMRK-UHFFFAOYSA-N 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
230000036983 biotransformation Effects 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000006227 byproduct Substances 0.000 description 3
238000011260 co-administration Methods 0.000 description 3
238000000576 coating method Methods 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
230000000378 dietary effect Effects 0.000 description 3
150000002118 epoxides Chemical class 0.000 description 3
230000005284 excitation Effects 0.000 description 3
125000001153 fluoro group Chemical group F* 0.000 description 3
229930195733 hydrocarbon Natural products 0.000 description 3
150000002430 hydrocarbons Chemical class 0.000 description 3
DFMAXQKDIGCMTL-UHFFFAOYSA-N isopimpinellin Chemical compound O1C(=O)C=CC2=C1C(OC)=C1OC=CC1=C2OC DFMAXQKDIGCMTL-UHFFFAOYSA-N 0.000 description 3
229960004469 methoxsalen Drugs 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
229940093932 potassium hydroxide Drugs 0.000 description 3
238000000746 purification Methods 0.000 description 3
239000011535 reaction buffer Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 2
RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
235000005979 Citrus limon Nutrition 0.000 description 2
244000131522 Citrus pyriformis Species 0.000 description 2
235000005976 Citrus sinensis Nutrition 0.000 description 2
240000002319 Citrus sinensis Species 0.000 description 2
NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 2
101710088194 Dehydrogenase Proteins 0.000 description 2
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 2
206010061598 Immunodeficiency Diseases 0.000 description 2
AJSPSRWWZBBIOR-UHFFFAOYSA-N Isobergapten Chemical compound O1C(=O)C=CC2=C1C(C=CO1)=C1C=C2OC AJSPSRWWZBBIOR-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 2
ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229910021627 Tin(IV) chloride Inorganic materials 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
125000002947 alkylene group Chemical group 0.000 description 2
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
235000021170 buffet Nutrition 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
239000002775 capsule Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000004821 distillation Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229960003580 felodipine Drugs 0.000 description 2
239000012467 final product Substances 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
125000004356 hydroxy functional group Chemical group O* 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000004571 lime Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
229960002509 miconazole Drugs 0.000 description 2
DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 2
229960003793 midazolam Drugs 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
229960001597 nifedipine Drugs 0.000 description 2
150000002978 peroxides Chemical class 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000004810 polytetrafluoroethylene Substances 0.000 description 2
229920001343 polytetrafluoroethylene Polymers 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000008213 purified water Substances 0.000 description 2
125000003373 pyrazinyl group Chemical group 0.000 description 2
229960000311 ritonavir Drugs 0.000 description 2
NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
125000004434 sulfur atom Chemical group 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
125000001544 thienyl group Chemical group 0.000 description 2
HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 2
229960003386 triazolam Drugs 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
239000003039 volatile agent Substances 0.000 description 2
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
IXZUPBUEKFXTSD-INMULRNOSA-N (R)-(+)-6',7'-dihydroxybergamottin Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC\C=C(CC[C@@H](O)C(C)(C)O)/C IXZUPBUEKFXTSD-INMULRNOSA-N 0.000 description 1
PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
KJDXYWIMMJVFLH-JLHYYAGUSA-N 7-[(e)-5-(3,3-dimethyloxiran-2-yl)-3-methylpent-2-enoxy]chromen-2-one Chemical compound C=1C=C2C=CC(=O)OC2=CC=1OC\C=C(/C)CCC1OC1(C)C KJDXYWIMMJVFLH-JLHYYAGUSA-N 0.000 description 1
QYYKWTUUCOTGNS-JIIJFUIFSA-N 7-[(e,6r)-6,7-dihydroxy-3,7-dimethyloct-2-enoxy]chromen-2-one Chemical compound C1=CC(=O)OC2=CC(OC\C=C(CC[C@@H](O)C(C)(C)O)/C)=CC=C21 QYYKWTUUCOTGNS-JIIJFUIFSA-N 0.000 description 1
ODRDTKMYQDXVGG-UHFFFAOYSA-N 8-methoxycoumarin Natural products C1=CC(=O)OC2=C1C=CC=C2OC ODRDTKMYQDXVGG-UHFFFAOYSA-N 0.000 description 1
QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
241000511343 Chondrostoma nasus Species 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
206010011416 Croup infectious Diseases 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
OOKSPQLCQUBEKU-MDWZMJQESA-N Epoxybergamottin Chemical compound C=12C=COC2=CC=2OC(=O)C=CC=2C=1OC\C=C(/C)CCC1OC1(C)C OOKSPQLCQUBEKU-MDWZMJQESA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
244000182067 Fraxinus ornus Species 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
206010053317 Hydrophobia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
235000019501 Lemon oil Nutrition 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000238367 Mya arenaria Species 0.000 description 1
241000206607 Porphyra umbilicalis Species 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
229910006074 SO2NH2 Inorganic materials 0.000 description 1
229910008433 SnCU Inorganic materials 0.000 description 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
206010047642 Vitiligo Diseases 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
125000005189 alkyl hydroxy group Chemical group 0.000 description 1
YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
235000013405 beer Nutrition 0.000 description 1
230000008901 benefit Effects 0.000 description 1
125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
OOKSPQLCQUBEKU-UHFFFAOYSA-N bergamottin epoxide Natural products C=12C=COC2=CC=2OC(=O)C=CC=2C=1OCC=C(C)CCC1OC1(C)C OOKSPQLCQUBEKU-UHFFFAOYSA-N 0.000 description 1
229940093797 bioflavonoids Drugs 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000004296 chiral HPLC Methods 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
239000001279 citrus aurantifolia swingle expressed oil Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
201000010549 croup Diseases 0.000 description 1
125000006165 cyclic alkyl group Chemical group 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
KJDXYWIMMJVFLH-UHFFFAOYSA-N epoxyaurapten Natural products C=1C=C2C=CC(=O)OC2=CC=1OCC=C(C)CCC1OC1(C)C KJDXYWIMMJVFLH-UHFFFAOYSA-N 0.000 description 1
IXZUPBUEKFXTSD-UHFFFAOYSA-N epoxybergamottin hydrate Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(CCC(O)C(C)(C)O)C IXZUPBUEKFXTSD-UHFFFAOYSA-N 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
229930003935 flavonoid Natural products 0.000 description 1
150000002215 flavonoids Chemical class 0.000 description 1
235000017173 flavonoids Nutrition 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
229960004884 fluconazole Drugs 0.000 description 1
RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
LIIALPBMIOVAHH-UHFFFAOYSA-N herniarin Chemical compound C1=CC(=O)OC2=CC(OC)=CC=C21 LIIALPBMIOVAHH-UHFFFAOYSA-N 0.000 description 1
JHGVLAHJJNKSAW-UHFFFAOYSA-N herniarin Natural products C1CC(=O)OC2=CC(OC)=CC=C21 JHGVLAHJJNKSAW-UHFFFAOYSA-N 0.000 description 1
239000002035 hexane extract Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229960001936 indinavir Drugs 0.000 description 1
CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000007689 inspection Methods 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
238000010829 isocratic elution Methods 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
229960004130 itraconazole Drugs 0.000 description 1
239000010501 lemon oil Substances 0.000 description 1
239000011968 lewis acid catalyst Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000000622 liquid--liquid extraction Methods 0.000 description 1
238000001172 liquid--solid extraction Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
QYYKWTUUCOTGNS-OJNOIJSXSA-N marmin Natural products O(C/C=C(\CC[C@@H](O)C(O)(C)C)/C)c1cc2OC(=O)C=Cc2cc1 QYYKWTUUCOTGNS-OJNOIJSXSA-N 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
201000005962 mycosis fungoides Diseases 0.000 description 1
DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
229930019673 naringin Natural products 0.000 description 1
229940052490 naringin Drugs 0.000 description 1
229960000884 nelfinavir Drugs 0.000 description 1
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
229940063121 neoral Drugs 0.000 description 1
229960000227 nisoldipine Drugs 0.000 description 1
229960005425 nitrendipine Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000002905 orthoesters Chemical class 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
238000012856 packing Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000002165 photosensitisation Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000003672 processing method Methods 0.000 description 1
238000010926 purge Methods 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
239000002994 raw material Substances 0.000 description 1
238000012552 review Methods 0.000 description 1
229940063122 sandimmune Drugs 0.000 description 1
230000001932 seasonal effect Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
241000894007 species Species 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000005556 structure-activity relationship Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
229960003708 sumatriptan Drugs 0.000 description 1
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
229960001967 tacrolimus Drugs 0.000 description 1
238000004885 tandem mass spectrometry Methods 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
235000007586 terpenes Nutrition 0.000 description 1
238000012956 testing procedure Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000004001 thioalkyl group Chemical group 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000007704 transition Effects 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 1
229960005041 troleandomycin Drugs 0.000 description 1
230000022814 xenobiotic metabolic process Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines Containing Plant Substances (AREA)
Fats And Perfumes (AREA)

OA1200000051A 1997-08-26 2000-02-24 Anti-first-pass effect compounds. OA11398A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US5638297P	1997-08-26	1997-08-26
US08/997,259 US6063809A (en)	1997-08-26	1997-12-23	Anti-first-pass effect compounds
US09/001,218 US6124477A (en)	1996-06-27	1997-12-30	Anti-first-pass effect compounds

Publications (1)

Publication Number	Publication Date
OA11398A true OA11398A (en)	2004-04-14

Family

ID=27356877

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200000051A OA11398A (en)	1997-08-26	2000-02-24	Anti-first-pass effect compounds.

Country Status (18)

Country	Link
EP (1)	EP1019042B1 (fr)
JP (1)	JP2001526177A (fr)
CN (2)	CN1155377C (fr)
AP (1)	AP2000001746A0 (fr)
AT (1)	ATE238786T1 (fr)
AU (1)	AU750224B2 (fr)
BR (1)	BR9812002A (fr)
CA (1)	CA2299503C (fr)
CZ (1)	CZ295411B6 (fr)
DE (1)	DE69814118T2 (fr)
DK (1)	DK1019042T3 (fr)
ES (1)	ES2199457T3 (fr)
IL (1)	IL134408A0 (fr)
NZ (1)	NZ502767A (fr)
OA (1)	OA11398A (fr)
PT (1)	PT1019042E (fr)
SI (1)	SI1019042T1 (fr)
WO (1)	WO1999009976A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1240831A3 (fr) *	2001-03-15	2003-06-04	Takasago International Corporation	Agent de prévention de la décoloration
US6752862B2 (en)	2001-03-16	2004-06-22	Takasago International Corporation	Color fading/discoloration preventive agent
EP1896075A2 (fr) *	2005-06-22	2008-03-12	LifeCycle Pharma A/S	Compositions pharmaceutiques comprenant du tacrolimus et un inhibiteur cyp3a4
JP5481746B2 (ja) *	2009-09-28	2014-04-23	公益財団法人東洋食品研究所	フロクマリン類の含有量を低減したイチジクの製造方法
WO2024223797A1 (fr)	2023-04-28	2024-10-31	Institut National de la Santé et de la Recherche Médicale	Utilisation d'inhibiteurs de cyp3a4 pour le traitement d'infections par le virus de l'hépatite d (vhd)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2168696B (en) *	1984-12-21	1989-01-11	Boehringer Biochemia Srl	Fluoro coumarins as antilymphoedema agents

1998
- 1998-08-26 SI SI9830480T patent/SI1019042T1/xx unknown
- 1998-08-26 DE DE69814118T patent/DE69814118T2/de not_active Expired - Lifetime
- 1998-08-26 CN CNB988090988A patent/CN1155377C/zh not_active Expired - Fee Related
- 1998-08-26 EP EP98942177A patent/EP1019042B1/fr not_active Expired - Lifetime
- 1998-08-26 NZ NZ502767A patent/NZ502767A/en unknown
- 1998-08-26 AU AU90288/98A patent/AU750224B2/en not_active Ceased
- 1998-08-26 WO PCT/US1998/017332 patent/WO1999009976A1/fr not_active Ceased
- 1998-08-26 CN CNA2004100339712A patent/CN1537856A/zh active Pending
- 1998-08-26 CA CA002299503A patent/CA2299503C/fr not_active Expired - Fee Related
- 1998-08-26 JP JP2000507366A patent/JP2001526177A/ja active Pending
- 1998-08-26 AP APAP/P/2000/001746A patent/AP2000001746A0/en unknown
- 1998-08-26 CZ CZ2000695A patent/CZ295411B6/cs not_active IP Right Cessation
- 1998-08-26 AT AT98942177T patent/ATE238786T1/de not_active IP Right Cessation
- 1998-08-26 ES ES98942177T patent/ES2199457T3/es not_active Expired - Lifetime
- 1998-08-26 IL IL13440898A patent/IL134408A0/xx unknown
- 1998-08-26 BR BR9812002-6A patent/BR9812002A/pt not_active Application Discontinuation
- 1998-08-26 DK DK98942177T patent/DK1019042T3/da active
- 1998-08-26 PT PT98942177T patent/PT1019042E/pt unknown
2000
- 2000-02-24 OA OA1200000051A patent/OA11398A/en unknown

Also Published As

Publication number	Publication date
CZ295411B6 (cs)	2005-08-17
DE69814118T2 (de)	2004-04-01
DK1019042T3 (da)	2003-08-25
CN1155377C (zh)	2004-06-30
PT1019042E (pt)	2003-09-30
CA2299503A1 (fr)	1999-03-04
CN1270519A (zh)	2000-10-18
SI1019042T1 (en)	2003-12-31
ATE238786T1 (de)	2003-05-15
ES2199457T3 (es)	2004-02-16
JP2001526177A (ja)	2001-12-18
EP1019042A1 (fr)	2000-07-19
AU750224B2 (en)	2002-07-11
IL134408A0 (en)	2001-04-30
CZ2000695A3 (cs)	2000-08-16
DE69814118D1 (en)	2003-06-05
AP2000001746A0 (en)	2000-03-31
WO1999009976A1 (fr)	1999-03-04
NZ502767A (en)	2001-11-30
EP1019042B1 (fr)	2003-05-02
CA2299503C (fr)	2006-08-22
AU9028898A (en)	1999-03-16
BR9812002A (pt)	2000-09-26
EP1019042A4 (fr)	2001-07-11
CN1537856A (zh)	2004-10-20

Publication	Publication Date	Title
US7514572B2 (en)	2009-04-07	Anti-first-pass effect compounds
US7576124B2 (en)	2009-08-18	Anti-first-pass effect compounds
US7576123B2 (en)	2009-08-18	Anti-first-pass effect compounds
US7919636B2 (en)	2011-04-05	Purifications of pomegranate ellagitannins and their uses thereof
US5962044A (en)	1999-10-05	Citrus extract
US6124477A (en)	2000-09-26	Anti-first-pass effect compounds
US5990154A (en)	1999-11-23	Anti-first-pass effect compounds and citrus extract
OA11398A (en)	2004-04-14	Anti-first-pass effect compounds.
JPH06100584A (ja)	1994-04-12	新規フラボノイド配糖体
KR100637263B1 (ko)	2006-10-23	정공피 추출물을 포함하는 뇌혈관계 질환의 예방 및치료를 위한 약학조성물
WO1998024316A1 (fr)	1998-06-11	Composes et extrait d'agrume diriges contre l'effet de premier passage
KR20050072177A (ko)	2005-07-11	권백 추출물을 포함하는 심혈관계 질환의 치료 및 예방을위한 약학조성물